Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Preparation Plan For Europe’s Unified Patent Court Delayed; UK General Election Spells More Uncertainty

Executive Summary

The failure of some EU member states to agree on the important provisional application phase of Europe’s unitary patent and Unified Patent Court could prevent the new system going live on schedule, as could the coming UK general election.

You may also be interested in...



Reasons For German Challenge To Unified Patent Court Emerge; Missing Brexit Deadline Could Prove Fatal

One of the grounds for the legal challenge to Germany’s ratification of the UPC system has a clear path to resolution but three other grounds might prove tricky. Meanwhile a newly published guide explains how to obtain, maintain and manage unitary patents.

Year’s Delay Possible For Europe’s Unified Patent Court As German Ratification Is Put On Hold

Plans to bring Europe’s new Unified Patent Court system into operation could be delayed for more than a year following a legal challenge to Germany’s ratification of the UPC Agreement that could have knock-on effects in the UK.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel